Reduction of ADAMTS13 Levels Predicts Mortality in SARS-CoV-2 Patients

Giovanni L. Tiscia; Giovanni Favuzzi; Antonio De Laurenzo; Filomena Cappucci; Lucia Fischetti; Lazzaro di Mauro; Giuseppe Miscio; Antonio Mirijello; Elena Chinni; Elvira Grandone; on behalf of CSS COVID-19 Group

doi:10.1055/s-0040-1716379

TH Open, Table of Contents

CC BY 4.0 · TH Open 2020; 04(03): e203-e206
DOI: 10.1055/s-0040-1716379

Letter to the Editor

Reduction of ADAMTS13 Levels Predicts Mortality in SARS-CoV-2 Patients

Authors

Giovanni L. Tiscia

¹Research Unit of Thrombosis and Hemostasis, Fondazione IRCCS “Casa Sollievo della Sofferenza,” San Giovanni Rotondo, Italy
Giovanni Favuzzi

¹Research Unit of Thrombosis and Hemostasis, Fondazione IRCCS “Casa Sollievo della Sofferenza,” San Giovanni Rotondo, Italy
Antonio De Laurenzo

¹Research Unit of Thrombosis and Hemostasis, Fondazione IRCCS “Casa Sollievo della Sofferenza,” San Giovanni Rotondo, Italy
Filomena Cappucci

¹Research Unit of Thrombosis and Hemostasis, Fondazione IRCCS “Casa Sollievo della Sofferenza,” San Giovanni Rotondo, Italy
Lucia Fischetti

¹Research Unit of Thrombosis and Hemostasis, Fondazione IRCCS “Casa Sollievo della Sofferenza,” San Giovanni Rotondo, Italy
Lazzaro di Mauro

²Transfusion Medicine and Laboratory Department, Fondazione IRCCS “Casa Sollievo della Sofferenza,” San Giovanni Rotondo, Italy
Giuseppe Miscio

²Transfusion Medicine and Laboratory Department, Fondazione IRCCS “Casa Sollievo della Sofferenza,” San Giovanni Rotondo, Italy
Antonio Mirijello

³Medical Department, Fondazione IRCCS “Casa Sollievo della Sofferenza,” San Giovanni Rotondo, Italy
Elena Chinni

¹Research Unit of Thrombosis and Hemostasis, Fondazione IRCCS “Casa Sollievo della Sofferenza,” San Giovanni Rotondo, Italy
Elvira Grandone

¹Research Unit of Thrombosis and Hemostasis, Fondazione IRCCS “Casa Sollievo della Sofferenza,” San Giovanni Rotondo, Italy

on behalf of CSS COVID-19 Group

Abstract

Full Text

References

References
1 Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood 2020; 135 (23) 2033-2040
2 Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020; 18 (04) 844-847
3 Varga Z, Flammer AJ, Steiger P. , et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet 2020; 395 (10234): 1417-1418
4 Marini JJ, Gattinoni L. Management of COVID-19 respiratory distress. JAMA [Internet] 2020;
5 Moake JL. Thrombotic microangiopathies. N Engl J Med 2002; 347 (08) 589-600
6 George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med 2014; 371 (07) 654-666
7 Coppo P, Adrie C, Azoulay E. , et al. Infectious diseases as a trigger in thrombotic microangiopathies in intensive care unit (ICU) patients?. Intensive Care Med 2003; 29 (04) 564-569
8 Masias C, Cataland SR. The role of ADAMTS13 testing in the diagnosis and management of thrombotic microangiopathies and thrombosis. Blood 2018; 132 (09) 903-910
9 Levi M, Scully M, Singer M. The role of ADAMTS-13 in the coagulopathy of sepsis. J Thromb Haemost 2018; 16 (04) 646-651
10 Vasileiadis I, Politou M, Dimopoulos S. , et al. Variation of endothelium-related hemostatic factors during sepsis. Microcirculation 2018; 25 (08) e12500
11 Chen J, Chung DW. Inflammation, von Willebrand factor, and ADAMTS13. Blood 2018; 132 (02) 141-147
12 Levi M, van der Poll T. Inflammation and coagulation. Crit Care Med 2010; 38 (2, Suppl): S26-S34
13 Keller TT, Mairuhu AT, de Kruif MD. , et al. Infections and endothelial cells. Cardiovasc Res 2003; 60 (01) 40-48
14 World Health Organization. Coronavirus disease (COVID-19) technical guidance: laboratory testing for 2019-nCoV in humans. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/laboratory-guidance . Accessed August 12, 2020
15 Kremer Hovinga JA, Zeerleder S, Kessler P. , et al. ADAMTS-13, von Willebrand factor and related parameters in severe sepsis and septic shock. J Thromb Haemost 2007; 5 (11) 2284-2290
16 Martin K, Borgel D, Lerolle N. , et al. Decreased ADAMTS-13 (a disintegrin-like and metalloprotease with thrombospondin type 1 repeats) is associated with a poor prognosis in sepsis-induced organ failure. Crit Care Med 2007; 35 (10) 2375-2382
17 Lin JJ, Chan OW, Hsiao HJ. , et al. Decreased ADAMTS 13 activity is associated with disease severity and outcome in pediatric severe sepsis. Medicine (Baltimore) 2016; 95 (16) e3374
18 Song J, Lee KA, Park TS, Park R, Choi JR. Linear relationship between ADAMTS13 activity and platelet dynamics even before severe thrombocytopenia. Ann Clin Lab Sci 2008; 38 (04) 368-375
19 Dhainaut J-F, Shorr AF, Macias WL. , et al. Dynamic evolution of coagulopathy in the first day of severe sepsis: relationship with mortality and organ failure. Crit Care Med 2005; 33 (02) 341-348
20 Mathieu J, Boucher S. Sepsis-associated coagulopathy: diagnosis with hematologic biomarkers and a novel hemostatic score that may predict the risk of developing a multiple organ dysfunction syndrome and a higher rate of mortality. Chest 2015; 148: 340A
21 Zhou F, Yu T, Du R. , et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395 (10229): 1054-1062
22 Zhang L, Yan X, Fan Q. , et al. D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. J Thromb Haemost 2020; 18 (06) 1324-1329
23 Sardu C, Gambardella J, Morelli MB, Wang X, Marfella R, Santulli G. Hypertension, thrombosis, kidney failure, and diabetes: is COVID-19 an endothelial disease? A comprehensive evaluation of clinical and basic evidence. J Clin Med 2020; 9 (05) 1417
24 Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol 2020; 7 (06) e438-e440

Supplementary Material

Supplementary Material (PDF)